Gendron L, Pintar J E, Chavkin C
Department of Pharmacology, Health Sciences Building, University of Washington, Seattle, WA 98195-7280, USA.
Neuroscience. 2007 Dec 19;150(4):807-17. doi: 10.1016/j.neuroscience.2007.09.060. Epub 2007 Oct 5.
Analgesic effects of delta opioid receptor (DOR) -selective agonists are enhanced during persistent inflammation and arthritis. Although the underlying mechanisms are still unknown, membrane density of DOR was shown to be increased 72 h after induction of inflammation, an effect abolished in mu opioid receptor (MOR) -knockout (KO) mice [Morinville A, Cahill CM, Kieffer B, Collier B, Beaudet A (2004b) Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain. Pain 109:266-273]. In this study, we demonstrated a crucial role of MOR in DOR-mediated antihyperalgesia. Intrathecal administration of the DOR selective agonist deltorphin II failed to induce antihyperalgesic effects in MOR-KO mice, whereas it dose-dependently reversed thermal hyperalgesia in wild-type mice. The antihyperalgesic effects of deltorphin II were blocked by naltrindole but not d-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2) (CTOP) suggesting that this agonist was mainly acting through DOR. SNC80-induced antihyperalgesic effects in MOR-KO mice were also attenuated as compared with littermate controls. In contrast, kappa opioid receptor knockout did not affect deltorphin II-induced antihyperalgesia. As evaluated using mice lacking endogenous opioid peptides, the regulation of DOR's effects was also independent of beta-endorphin, enkephalins, or dynorphin opioids known to be released during persistent inflammation. We therefore conclude that DOR-mediated antihyperalgesia is dependent on MOR expression but that activation of MOR by endogenous opioids is probably not required.
在持续性炎症和关节炎期间,δ阿片受体(DOR)选择性激动剂的镇痛作用会增强。尽管其潜在机制尚不清楚,但炎症诱导72小时后,DOR的膜密度显示增加,而在μ阿片受体(MOR)基因敲除(KO)小鼠中这种效应消失[Morinville A, Cahill CM, Kieffer B, Collier B, Beaudet A(2004b)μ阿片受体基因敲除可预防慢性炎性疼痛诱导的δ阿片受体转运变化。疼痛109:266 - 273]。在本研究中,我们证明了MOR在DOR介导的抗痛觉过敏中起关键作用。鞘内注射DOR选择性激动剂强啡肽II未能在MOR-KO小鼠中诱导抗痛觉过敏效应,而在野生型小鼠中它能剂量依赖性地逆转热痛觉过敏。强啡肽II的抗痛觉过敏效应被纳曲吲哚阻断,但未被d-苯丙氨酸-半胱氨酸-酪氨酸-D-色氨酸-鸟氨酸-苏氨酸-苯丙氨酸-苏氨酸-酰胺(CTOP)阻断,这表明该激动剂主要通过DOR起作用。与同窝对照相比,SNC80在MOR-KO小鼠中诱导的抗痛觉过敏效应也减弱。相反,κ阿片受体基因敲除不影响强啡肽II诱导的抗痛觉过敏。如使用缺乏内源性阿片肽的小鼠所评估的那样,DOR效应的调节也独立于已知在持续性炎症期间释放的β-内啡肽、脑啡肽或强啡肽类阿片。因此,我们得出结论,DOR介导的抗痛觉过敏依赖于MOR的表达,但内源性阿片对MOR的激活可能并非必需。